Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
RareStone Group logo — To become the leading company in China rare disease market

RareStone Group

To become the leading company in China rare disease market

Founded 2019 China China 25 employees Series A Total: $80.00M Pharmaceutical

General Information

Company Name RareStone Group
Founded Year 2019
Location China China +1
Employees 25
Industries Pharmaceutical
Funding Stage Series A
Social

Get notified when RareStone Group moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About RareStone Group

RareStone Group is on a mission to revolutionize the rare disease market in China. The company's subsidiaries, Citrine Medicine and Zircon Health, are pioneering a comprehensive ecosystem for rare diseases. Citrine Medicine focuses on delivering effective and affordable therapeutic solutions across four key areas, while Zircon Health aims to build a patient-centered service platform leveraging AI and big data analytics. In July 2020, RareStone Group secured a significant USD80 million Series A financing with key investments from Eight Roads Ventures, F-Prime Capital, and Vivo Capital. Founded in 2019, the company aims to become the leading support system for the rare disease community in China, providing access to the best global treatment protocols and medications. With its forward-thinking approach and substantial backing, RareStone Group is poised to make a substantial impact in the rare disease market in China and beyond.

Taxonomy: Rare diseases, Pharmaceuticals, Healthcare services, China market, Therapeutic solutions, Service platform, Rare disease community, Series A financing, Investors, Neurology, Endocrinology, AI and big data analytics, Patient-centered care, Ecosystem development

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 6
Investor Investor Investor Investor Investor Investor
13 Jul 2020

RareStone Group Alternatives & Competitors

RareStone Group vs
VISEN Pharmaceuticals
VISEN Pharmaceuticals China

Achieve better treatment processes and outcomes by combining global expertise and strength in endocr...

Series B
42 employees
Biotechnology, Life Sciences
Compare RareStone Group vs VISEN Pharmaceuticals
RareStone Group vs
BioInnova
BioInnova Australia

Integrative Innovation and Medicine

20 employees
Manufacturing, Pharmaceutical
Compare RareStone Group vs BioInnova

FAQ About RareStone Group

To become the leading company in China rare disease market
RareStone Group was founded in 2019.
RareStone Group is headquartered in China.
RareStone Group operates in the following industries: Pharmaceutical.
RareStone Group has approximately 25 employees.
RareStone Group has completed 1 funding round, raising a total of $80.00M. The latest funding stage is Series A.
Top alternatives and competitors to RareStone Group include VISEN Pharmaceuticals, BioInnova. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RareStone Group and VISEN Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors RareStone Group and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy